Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Pfizer Breakthrough Growth Initiative

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 7
Average round size
The average size of a deal this fund participated in
Portfolio companies 7
Rounds per year 3.50
Lead investments 3
Exits 5
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Biopharma
  • Medical
  • Health Care

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pfizer Breakthrough Growth Initiative:
Typical Co-investors
Pfizer Breakthrough Growth Initiative is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pfizer Breakthrough Growth Initiative:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aegon Capital Management Canada, Ontario, Toronto
Alsthom industries -
Amesto Solutions Norway, Oslo
BENE Asia Capital -
CheckAlt -
CHINA.COM Beijing, Beijing, China
Concrete Ventures Canada, Halifax, Nova Scotia
Frontive Holding Limited -
German Federal Ministry of Education and Research (BMBF) Bonn, Germany, Nordrhein-Westfalen
GunnAllen Venture Partners Florida, Tampa, United States
InCrowd Capital Nashville, Tennessee, United States
North Star Equity Investment Partners -
Numenor Ventures California, Santa Barbara, United States
RP Partners California, Los Angeles, United States
SeriesG California, San Francisco, United States
SparkLabs Taipei New Taipei, Taiwan
Stylebread Hokkaido, Hokkaido Prefecture, Japan
Tera Capital Corporation Canada, Ontario, Toronto
TR Aeroventures -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

AgomAb Therapeutics

Health Care
$45M13 Jul 2022 Ghent, East Flanders, Belgium

Akero Therapeutics

Life Science
$25M16 Jun 2022 Cambridge, Massachusetts, United States

Cardiff Oncology

Health Diagnostics
$15M18 Nov 2021 San Diego, California, United States

Vedanta Biosciences

Business Development
Drug Discovery
$25M12 Jan 2021 Cambridge, Massachusetts, United States

Homology Medicines

Alternative Medicine
Health Care
$60M09 Nov 2020 Massachusetts, United States

Trillium Therapeutics

Clinical Trials
$25M08 Sep 2020 Ontario


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pfizer Breakthrough Growth Initiative?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: